Core Insights - MiNK Therapeutics has received a non-dilutive grant from the National Institute of Allergy and Infectious Diseases (NIAID) to support the development of its allogeneic invariant natural killer T (iNKT) cell therapy platform for preventing and treating graft-versus-host disease (GvHD) in high-risk hematopoietic stem cell transplantation (HSCT) settings [1][2] Company Overview - MiNK Therapeutics is a clinical-stage biopharmaceutical company focused on developing allogeneic iNKT cell therapies and precision-targeted immune technologies [4] - The company's lead asset, AGENT-797, is an off-the-shelf iNKT cell therapy currently in clinical development for GvHD, solid tumors, and critical pulmonary immune collapse [4] - MiNK is advancing a pipeline of T cell receptor (TCR)-based therapies and neoantigen discovery tools aimed at enabling tumor- and tissue-specific immune activation [4] Research and Development - The collaboration with the University of Wisconsin aims to leverage expertise in transplant immunology to enhance the efficacy of iNKT cells in managing GvHD while preserving the patient's ability to fight infections [3] - iNKT cells are recognized for their potential to regulate immune responses, promote tissue repair, and suppress inflammatory pathways, making them suitable for addressing GvHD complications [2][3] Market Need - Nearly 50% of patients undergoing allogeneic stem cell transplants are at risk for GvHD, highlighting a significant unmet medical need in this area [2]

Core Viewpoint - OceanPal Inc. has signed a Memorandum of Agreement to sell the dry bulk vessel "Protefs" for a price of US$7 million, with delivery scheduled by June 17, 2025 [1] Company Overview - OceanPal Inc. is a global provider of shipping transportation services, focusing on the ownership and operation of dry bulk vessels and product tankers [3] - The company engages in the seaborne transportation of bulk commodities such as iron ore, coal, and grain, as well as refined petroleum products [3] - OceanPal's fleet primarily operates on time charter trips with short to medium duration and spot charters, aiming to maximize long-term shareholder value [3] Fleet Composition - Following the sale of "Protefs," OceanPal's fleet will consist of 2 Panamax dry bulk vessels and 1 MR2 tanker vessel [2]

Deployment Strengthens Company’s Position as Leading Provider of AI-Powered Screening Solutions for Critical Infrastructure Shipment of another Sentinel Fixed Gantry CT underway — advancing AI-powered security screening across critical infrastructure Shipment of another Sentinel Fixed Gantry CT underway — advancing AI-powered security screening across critical infrastructure Shipment of another Sentinel Fixed Gantry CT underway — advancing AI-powered security screening across critical infrastructure Atla ...

Barnes v. Felix expands window of liability to include the totality of circumstances—renewing focus on officer’s actions during the pre-escalation period. MIAMI, June 02, 2025 (GLOBE NEWSWIRE) -- Wrap Technologies, Inc, (NASDAQ: WRAP) (“Wrap” or, the “Company”), a global leader in innovative public safety technologies and non-lethal tools, today issues a letter to stockholders from Founder and CEO, Scot Cohen. Chairman and CEO Letter to Stockholders Fellow Stockholders, Law-enforcement tools, technologies, ...

Company Overview - Alvotech is a global biotech company focused on the development and manufacture of biosimilar medicines for patients worldwide [3] - The company aims to be a leader in the biosimilar space by delivering high-quality, cost-effective products and services through a fully integrated approach and broad in-house capabilities [3] - Alvotech has launched two biosimilars and has a development pipeline targeting autoimmune disorders, eye disorders, osteoporosis, respiratory diseases, and cancer [3] Strategic Partnerships - Alvotech has formed a network of strategic commercial partnerships to enhance its global reach and leverage local expertise in various markets, including the United States, Europe, Japan, China, and parts of South America, Africa, and the Middle East [3] - Notable commercial partners include Teva Pharmaceuticals, STADA Arzneimittel AG, Fuji Pharma Co., Ltd, and Dr. Reddy's, among others, each covering unique products and territories [3] Upcoming Events - Alvotech will participate in the Jefferies Global Healthcare Conference 2025 in New York from June 3-5, 2025 [1] - Dr. Balaji Prasad, Chief Strategy Officer, will present recent business updates on June 5, 2025, from 10:30 am to 11:00 am EDT [1] - A live video webcast of the presentation will be available to the public, with a recording accessible for 90 days post-event [2]

AB “Ignitis grupė” (hereinafter – the Group) informs that on 2 June 2025 it has signed a financing agreement with the European Bank for Reconstruction and Development for a loan of EUR 60 million (hereinafter – the Loan), which will be used by its subsidiary UAB “Ignitis” to develop a public EV fast charging network in the Baltics.The Loan is granted for a period of 10 years. The other terms and conditions of the Loan are standard for corporate financing.The Loan will finance the installation of up to 600 E ...

Fit-for-purpose Facility Will Provide Significant Operational Flexibility as the Company Continues to Execute on its Long-Term Growth StrategyLIVERMORE, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- FormFactor, Inc. (NASDAQ: FORM), a leading provider of test and measurement technologies for the semiconductor industry, today announced that it has purchased a manufacturing site in Farmers Branch, Texas. The site, which comprises four structures and includes 50,000 square feet of clean room space, was purchased fo ...

WASHINGTON, June 02, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”), today announced the pricing of an underwritten registered direct offering of 7,518,797 shares of its common stock at a price of $6.65 per share to a single fundamental institutional investor. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $50.0 million. The offering is expected to close on or abo ...

ATHENS, Greece, June 02, 2025 (GLOBE NEWSWIRE) -- Diana Shipping Inc. (NYSE: DSX), (the “Company”), a global shipping company specializing in the ownership and bareboat charter-in of dry bulk vessels, today announced that through a separate wholly-owned subsidiary, it has entered into a time charter contract with Bohai Ocean Shipping (Singapore) Holding Pte. Ltd., for one of its Newcastlemax dry bulk vessels, the m/v Newport News. The gross charter rate is US$25,000 per day, minus a 5.00% commission paid to ...

Core Viewpoint - CERo Therapeutics Holdings, Inc. has significantly expanded its intellectual property portfolio with the granting of multiple patents, enhancing its position in the immunotherapy market focused on engineered T cell therapeutics [1][5][6]. Patent Developments - The USPTO granted U.S. Patent No. 12,291,557 for the chimeric TIM4 receptor, which protects design aspects of the lead compound CER-1236 [2]. - The European Patent Office allowed European Patent Application No. 1882166.7, covering a chimeric engulfment receptor that further protects CER-1236's design aspects already granted in the U.S., Japan, and China [3]. - U.S. Patent No. 12,303,551 was granted for cellular immunotherapy compositions, covering combination therapies involving CER-1236, which may enhance treatment options for cancer [4]. Intellectual Property Portfolio - CERo's intellectual property now includes a total of 18 issued patents and allowed patent applications internationally, with 9 total patent families providing protection until 2042 in the United States [5][6]. Company Strategy and Future Plans - The CEO of CERo emphasized the importance of expanding the intellectual property portfolio to ensure market success and highlighted the novelty of the CER-T technology [6]. - The company anticipates updates on clinical trial progress for acute myeloid leukemia (AML) and plans to initiate human trials for ovarian and non-small cell lung cancers [6][7].